HR and breast cancer: With respect to the present study, it should be noted that the HER2+ tumors presented with more aggressive features than the HER2− cases, which may have impacted the results, but also reflects the inherent differences between aggressive HER2+ breast cancer and the more indolent luminal cases [36,37], since the majority of the HER2− cases were HR+.